210 related articles for article (PubMed ID: 26060354)
1. Long-term efficacy and safety of rabeprazole in patients taking low-dose aspirin with a history of peptic ulcers: a phase 2/3, randomized, parallel-group, multicenter, extension clinical trial.
Fujishiro M; Higuchi K; Kato M; Kinoshita Y; Iwakiri R; Watanabe T; Takeuchi T; Sugisaki N; Okada Y; Ogawa H; Arakawa T; Fujimoto K;
J Clin Biochem Nutr; 2015 May; 56(3):228-39. PubMed ID: 26060354
[TBL] [Abstract][Full Text] [Related]
2. Randomised clinical trial: prevention of recurrence of peptic ulcers by rabeprazole in patients taking low-dose aspirin.
Iwakiri R; Higuchi K; Kato M; Fujishiro M; Kinoshita Y; Watanabe T; Takeuchi T; Yamauchi M; Sanomura M; Nakagawa H; Sugisaki N; Okada Y; Ogawa H; Arakawa T; Fujimoto K
Aliment Pharmacol Ther; 2014 Oct; 40(7):780-95. PubMed ID: 25100080
[TBL] [Abstract][Full Text] [Related]
3. Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study.
Kawai T; Oda K; Funao N; Nishimura A; Matsumoto Y; Mizokami Y; Ashida K; Sugano K
Gut; 2018 Jun; 67(6):1033-1041. PubMed ID: 29196436
[TBL] [Abstract][Full Text] [Related]
4. Rabeprazole reduces the recurrence risk of peptic ulcers associated with low-dose aspirin in patients with cardiovascular or cerebrovascular disease: a prospective randomized active-controlled trial.
Sanuki T; Fujita T; Kutsumi H; Hayakumo T; Yoshida S; Inokuchi H; Murakami M; Matsubara Y; Kuwayama H; Kawai T; Miyaji H; Fujisawa T; Terao S; Yamazaki Y; Azuma T;
J Gastroenterol; 2012 Nov; 47(11):1186-97. PubMed ID: 22526273
[TBL] [Abstract][Full Text] [Related]
5. Similar Efficacy of Proton-Pump Inhibitors vs H2-Receptor Antagonists in Reducing Risk of Upper Gastrointestinal Bleeding or Ulcers in High-Risk Users of Low-Dose Aspirin.
Chan FK; Kyaw M; Tanigawa T; Higuchi K; Fujimoto K; Cheong PK; Lee V; Kinoshita Y; Naito Y; Watanabe T; Ching JY; Lam K; Lo A; Chan H; Lui R; Tang RS; Sakata Y; Tse YK; Takeuchi T; Handa O; Nebiki H; Wu JC; Abe T; Mishiro T; Ng SC; Arakawa T
Gastroenterology; 2017 Jan; 152(1):105-110.e1. PubMed ID: 27641510
[TBL] [Abstract][Full Text] [Related]
6. Rabeprazole Coadministration Controls Ulcer Recurrence in Patients on Low-dose Aspirin Therapy: A Multicenter Prospective Study.
Kinoshita Y; Kato M; Sugizaki K; Ikeuchi S
Intern Med; 2023 Feb; 62(4):495-502. PubMed ID: 35908971
[TBL] [Abstract][Full Text] [Related]
7. Mucosal Healing Effectiveness and Safety of Anaprazole, a Novel PPI, vs. Rabeprazole in Patients With Duodenal Ulcers: A Randomized Double-Blinded Multicenter Phase II Clinical Trial.
Shu X; Zhu Z; Fu Y; Zhang Z; Wang J; Li X; He S; Fan H; Liu S; Zhang G; Tang J; Huang C; Du Q; Wang X; Xu B; Du Y; Chen Q; Wang B; Chen Y; Duan X; Xie Y; Huo L; Hou X; Lu N
Front Med (Lausanne); 2021; 8():690995. PubMed ID: 34336894
[No Abstract] [Full Text] [Related]
8. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial.
Taha AS; McCloskey C; Prasad R; Bezlyak V
Lancet; 2009 Jul; 374(9684):119-25. PubMed ID: 19577798
[TBL] [Abstract][Full Text] [Related]
9. Rabeprazole: a review of its use in acid-related gastrointestinal disorders.
Langtry HD; Markham A
Drugs; 1999 Oct; 58(4):725-42. PubMed ID: 10551440
[TBL] [Abstract][Full Text] [Related]
10. Misoprostol for small bowel ulcers in patients with obscure bleeding taking aspirin and non-steroidal anti-inflammatory drugs (MASTERS): a randomised, double-blind, placebo-controlled, phase 3 trial.
Taha AS; McCloskey C; McSkimming P; McConnachie A
Lancet Gastroenterol Hepatol; 2018 Jul; 3(7):469-476. PubMed ID: 29754836
[TBL] [Abstract][Full Text] [Related]
11. Randomised clinical trial: rabeprazole plus aspirin is not inferior to rabeprazole plus clopidogrel for the healing of aspirin-related peptic ulcer.
Luo JC; Huang KW; Leu HB; Chen LC; Hou MC; Li CP; Lu CL; Lin HC; Lee FY; Lee SD
Aliment Pharmacol Ther; 2011 Sep; 34(5):519-25. PubMed ID: 21726257
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of twice-daily rabeprazole maintenance therapy for patients with reflux esophagitis refractory to standard once-daily proton pump inhibitor: the Japan-based EXTEND study.
Kinoshita Y; Kato M; Fujishiro M; Masuyama H; Nakata R; Abe H; Kumagai S; Fukushima Y; Okubo Y; Hojo S; Kusano M
J Gastroenterol; 2018 Jul; 53(7):834-844. PubMed ID: 29188387
[TBL] [Abstract][Full Text] [Related]
13. Teprenone for the prevention of low-dose aspirin-induced gastric mucosal injury in
Chitapanarux T; Lertprasertsuke N; Kongnak A
Scand J Gastroenterol; 2019 Oct; 54(10):1199-1204. PubMed ID: 31591940
[No Abstract] [Full Text] [Related]
14. Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions.
Ng FH; Wong SY; Lam KF; Chu WM; Chan P; Ling YH; Kng C; Yuen WC; Lau YK; Kwan A; Wong BC
Gastroenterology; 2010 Jan; 138(1):82-8. PubMed ID: 19837071
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the efficacy of rabeprazole 10 mg and omeprazole 20 mg for the healing rapidity of peptic ulcer diseases.
Ji S; Kim HS; Kim JW; Jee MK; Park KW; Uh Y; Lee DK; Song JS; Baik SK; Kwon SO
J Gastroenterol Hepatol; 2006 Sep; 21(9):1381-7. PubMed ID: 16911680
[TBL] [Abstract][Full Text] [Related]
16. Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease. Rebeprazole Study Group.
Caos A; Moskovitz M; Dayal Y; Perdomo C; Niecestro R; Barth J
Am J Gastroenterol; 2000 Nov; 95(11):3081-8. PubMed ID: 11095321
[TBL] [Abstract][Full Text] [Related]
17. Effect of high-dose oral rabeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers.
Kim HK; Kim JS; Kim TH; Kim CW; Cho YS; Kim SS; Chae HS; Han SW; Park YW; Son HS; Min JY; Cho GJ; Bag JS; Choi SO
Gastroenterol Res Pract; 2012; 2012():317125. PubMed ID: 23049546
[TBL] [Abstract][Full Text] [Related]
18. Cytoprotective agent for peptic ulcer prevention in patients taking dual antiplatelet agents: A randomized, double-blind placebo-controlled trial.
Pittayanon R; Piyachaturawat P; Rerknimitr R; Prueksapanich P; Chaitongrat S; Lertsuwunseri V; Srimahachota S; Mahachai V
J Gastroenterol Hepatol; 2019 Sep; 34(9):1517-1522. PubMed ID: 30919492
[TBL] [Abstract][Full Text] [Related]
19. Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States.
Caos A; Breiter J; Perdomo C; Barth J
Aliment Pharmacol Ther; 2005 Aug; 22(3):193-202. PubMed ID: 16091056
[TBL] [Abstract][Full Text] [Related]
20. Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double-blind, multicenter, European trial. The European Rabeprazole Study Group.
Thjodleifsson B; Beker JA; Dekkers C; Bjaaland T; Finnegan V; Humphries TJ
Dig Dis Sci; 2000 May; 45(5):845-53. PubMed ID: 10795744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
